Efficacy of Intensive Granulocyte and Monocyte Apheresis in Patients with Pouchitis

Efficacy of Intensive Granulocyte and Monocyte Apheresis in Patients with Pouchitis - Efficacy of Intensive Granulocyte and Monocyte Apheresis in Patients with Pouchitis

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000010207

Enrollment

Registered

2013-03-11

Start date

2013-03-11

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pouchitis

Interventions

Patients to receive 10 GMA sessions at a frequency of 2 sessions per consecutive week

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Patients with a current episode of active pouchitis defined as having a pouchitis disease activity index of > 7 after IPAA for UC as confirmed by endoscopy and histology. 2.Patients who have endoscopically detectable lesion. 3.Patients with pouchitis refractory to antibiotics including metronidazole, and ciprofloxacin.

Exclusion criteria

Exclusion criteria: 1.Patients whose granulocyte number is under 2,000/mm3 2.Patients who have or is suspected severe infections.

Design outcomes

Primary

Measure	Time frame
Remission rate (PDAI<7)	—

Secondary

Measure	Time frame
1. Reduction of fecal markers (calprotectin, lactoferrin), C-reactive protein (CRP), and white blood cell count (WBC). 2. Improvement of endoscopic index reflecting healing of pouchitis lesions. 3. Reduction of the PDAI score 4. Correlation of fecal markers with the PDAI score	—

Countries

Japan

Contacts

Public ContactToshiaki Watanabe, M.D., Ph.D.

Faculty of Medicine, University of Tokyo Surgery

toshwatanabe@yahoo.co.jp03-5800-8653

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026